Research Topic · Peer-Reviewed

Myeloma Cells

Myeloma cells are malignant plasma cells that proliferate clonally within the bone marrow and give rise to multiple myeloma, a cancer of the terminally differentiated B-lymphocyte lineage. Derived from a single transformed plasma cell, they typically secrete a monoclonal immunoglobulin or free light chain, the parap…

Curated from this journal's research 📚 6 peer-reviewed articles cited Cited 9× across the literature 🔖 ISSN 2372-6601 🗓 Reviewed July 2026

Overview

Myeloma cells are malignant plasma cells that proliferate clonally within the bone marrow and give rise to multiple myeloma, a cancer of the terminally differentiated B-lymphocyte lineage. Derived from a single transformed plasma cell, they typically secrete a monoclonal immunoglobulin or free light chain, the paraprotein detectable in serum or urine, and depend on supportive interactions with the marrow microenvironment for survival and expansion. Their accumulation suppresses normal haematopoiesis and disrupts bone homeostasis, producing the characteristic features of anaemia, osteolytic bone disease and pathological fracture, hypercalcaemia, renal impairment, and susceptibility to infection. Myeloma cells are genomically heterogeneous, harbouring recurrent chromosomal translocations, copy-number changes, and subclonal evolution that drive disease progression and treatment resistance. Related plasma cell disorders illustrate the spectrum of this biology, including extramedullary and extraosseous plasmacytoma, plasma cell pleocytosis, and the lymphoplasmacytic proliferation of Waldenström's macroglobulinaemia. Research on myeloma cells addresses their pathogenesis, the mobilisation and collection of autologous stem cells for transplantation, complications of marrow involvement, and the development of targeted, immunomodulatory, and immune-based therapies. Characterising the molecular dependencies and microenvironmental signals that sustain myeloma cells remains central to improving diagnosis, risk stratification, and durable disease control in this incurable but increasingly treatable malignancy.

Research published in this journal

6 peer-reviewed articles, ranked by relevance. Each links to its DOI.

How this research is being cited

The 6 articles above have been cited 9 times in the scholarly literature. Citation data via OpenAlex and Crossref, updated Jun 2026.

A sample of recent works citing this journal's research on Myeloma Cells, linking to each citing work.

Editorial oversight

Curated from peer-reviewed research published in Hematology and Oncology Research (ISSN 2372-6601).

Journal editorial board
Jayadev Manikkam Umakanthan · United States Shuaiying Cui · United States Benedetto Sacchetti · Italy

This page summarises published research for orientation; it is not medical or professional advice.